Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Naoki Ishiguro¹, Tatsuya Atsumi², Masayoshi Harigai³, Tsuneyo Mimori⁴, Norihiro Nishimoto⁵, Takayuki Sumida⁶, Tsutomu Takeuchi⁷, Yoshiya Tanaka⁸, Nobuhiro Takagi⁹, Ayako Nakasone¹⁰ and Hisashi Yamanaka¹¹, ¹Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Phamacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ⁵Osaka Rheumatology Clinic, Osaka, Japan, ⁶Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Medical Science, Chugai Pharmaceutical, Tokyo, Japan, ¹⁰Chugai Pharmaceutical Co. Ltd, Tokyo, Japan, ¹¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…
Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^2,4, Chitra Karki², YouFu Li⁴, Joel M. Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^2,7, ¹Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…
Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^1,4, Chitra Karki¹, YouFu Li⁴, Joel Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^1,7, ¹Corrona, LLC, Southborough, MA, ²Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
Abstract Number: 2782 • 2015 ACR/ARHP Annual Meeting
Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Hiroshi Uda¹, Koji Shigematsu², Yoshitaka Ishizaki² and Osamu Saiki^1,3, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan, ³Rheumatology, Shiraishi Hospital, Imabari, Japan
Background/Purpose: For active rheumatoid arthritis patients with inadequate response to synthetic disease modifying antirheumatic drugs (DMARDs), biologic agents are indicated. However, the cost of biologics,…
Abstract Number: 2506 • 2014 ACR/ARHP Annual Meeting
Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab
Tamao Nakashita¹, Shinji Motojima² and Akira Jibatake³, ¹[email protected], Kameda Medical Center, Kamogawa-city, Japan, ²[email protected], Kameda Medical Center, Kamogawa City, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose : Tocilizumab (TCZ) is a monoclonal anti-IL-6 receptor antibody, and is very effective in controlling RA activity. However we had noticed that the change…
Abstract Number: 2508 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients
Virginia Ruiz-Esquide¹, Azucena Gonzalez-Navarro², Jordi Yagüe³, Jose Inciarte-Mundo¹, M. Victoria Hernández¹, Julio Ramirez¹, Sonia Cabrera-Villalba¹, Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Immunology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ³Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain
Background/Purpose Tocilizumab (TCZ) is a humanized monoclonal antibody against interleukin-6 receptor used for the treatment of active rheumatoid arthritis (RA). The response to this treatment…
Abstract Number: 2481 • 2014 ACR/ARHP Annual Meeting
Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDsÂ in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months
Jacques Tebib¹, Isabelle Idier², Mathieu Coudert³, David Pau⁴, Rene-Marc Flipo⁵ and Jean-Francis Maillefert⁶, ¹Rheumatology, University Hospital Lyon, Lyon, France, ²Chugai Pharma, La Defense, France, ³Statistics, Experis IT, Nanterre, France, ⁴Statistics, Roche, Boulogne-Billancourt, France, ⁵Rheumatology, University Hospital Lille, Lille, France, ⁶Rheumatology, University Hospital Dijon, Dijon, France
Background/Purpose Baseline factors influencing the use of tocilizumab (TCZ) in monotherapy (Mono) instead of combination with DMARDs (Combo) in real-life practice in RA patients (pts)…
Abstract Number: 2479 • 2014 ACR/ARHP Annual Meeting
Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis
Shuntaro Saito, Keisuke Izumi, Yuko Kaneko, Katsuya Suzuki and Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Interleukin-6 (IL-6) is considered a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) is a monoclonal antibody which binds to membrane-bound…
Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT
Koichi Okamura¹, Yukio Yonemoto¹, Chisa Okura² and Kenji Takagishi¹, ¹Orthopaedic Surgery, Gunma University, Maebashi, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
Abstract Number: 1912 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency
Shunsuke Mori, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan
Background/Purpose: Renal involvement is relatively common in rheumatoid arthritis (RA) patients. Recent randomized controlled trials of anti-tumor necrosis factor-α (anti-TNFα) showed that the concomitant administration…
Abstract Number: 1906 • 2014 ACR/ARHP Annual Meeting
IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Atsuma Nishiwaki¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Isamu Yokoe¹, Noboru Kitamura², Hidetake Shiraiwa¹, Takamasa Nozaki¹, Hirotake Inomata², Natsumi Ikumi⁴, Kaita Sugiyama¹, Yousuke Nagasawa¹ and Masami Takei⁵, ¹Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Radiology, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁵Dept of Med Rheumatology, Nihon University School of Medicine, Itabashi Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a 1.5–2.0 fold higher risk of developing congestive heart failure (CHF) than the general population. Small increases in…
Abstract Number: 1533 • 2014 ACR/ARHP Annual Meeting
Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis
Hiroshi Uda¹, Koji Shigematsu² and Osamu Saiki¹, ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: The treatment of active rheumatoid arthritis (RA) patients are usually started with synthetic disease modifying antirheumatic drugs (DMARDs), but when adequate response are not…
Abstract Number: 1468 • 2014 ACR/ARHP Annual Meeting
Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA
Kazuyuki Yoshizaki, Osaka University, Osaka, Japan
Background/Purpose AA amyloidosis is a serious complication of chronic inflammatory and infectious diseases resulting from the deposition of amyloid A protein. Serum amyloid A (SAA),…
Abstract Number: 1179 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging
Michihito Kono¹, Shinsuke Yasuda¹, Kazumasa Ohmura¹, Tomoko Fukui¹, Sanae Shimamura¹, Ikuma Nakagawa¹, Atsushi Noguchi¹, Haruki Shida¹, Toshiyuki Watanabe¹, Yuka Shimizu¹, Takashi Kurita¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Keita Sakamoto², Tamotsu Kamishima³ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Hokkaido University, Faculty of Health Science, Sapporo, Japan
Background/Purpose: Magnetic Resonance Imaging (MRI) has been established as a useful modality to evaluate synovitis, bone edema, and bone erosion in patients with rheumatoid arthritis…
Abstract Number: 506 • 2014 ACR/ARHP Annual Meeting
Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis
Osamu Saiki¹, Hiroshi Uda¹ and Koji Shigematsu², ¹Rheumatology, Higashiosaka City General Hospital, Higashiosaka, Japan, ²Orthopedics, Higashiosaka City General Hospital, Higashiosaka, Japan
Background/Purpose: For active rheumatoid arthritis (RA) patients with inadequate response to synthetic DMARDs, biologic agents, such as TNF inhibitor and IL-6 receptor inhibitor, are indicated.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].